Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL613497 Target Snapshot

Hepatitis B virus · ORGANISM · Hepatitis B virus

Back to Search Search this target Browse approvals Evidence Card
4,226Compounds
1,536Assays
30Approved Drugs
5,968.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Hepatitis B virus as ChEMBL target CHEMBL613497. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Hepatitis B virus
ORGANISM · Hepatitis B virus
As of 2026-09-13
ChEMBL target ID
CHEMBL613497
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Hepatitis B virus still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameHepatitis B virus
Target TypeORGANISM
OrganismHepatitis B virus
ChEMBL ↗ NCBI Taxonomy ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelHepatitis B virus
UniProt AccessionN/A

Hepatitis B virus

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Hepatitis B virus.

Review nameHepatitis B virus
OrganismHepatitis B virus
Clinical Profile

Clinical Phase Distribution

30
Approved
12
Phase III
16
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC503,200.0
EC502,768.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5314362 10.22 IC50 0.06 Approved
CHEMBL483 10.19 EC50 0.064 Clinical
CHEMBL5285547 10.0 EC50 0.1 Preclinical
CHEMBL4875146 9.7 EC50 0.2 Preclinical
CHEMBL5206918 9.7 IC50 0.2 Preclinical
CHEMBL5180441 9.7 IC50 0.2 Preclinical
CHEMBL4647919 9.6 EC50 0.25 Preclinical
CHEMBL4859319 9.57 EC50 0.27 Preclinical
CHEMBL5314362 9.46 EC50 0.35 Approved
CHEMBL473882 9.37 IC50 0.43 Preclinical
Distribution

pChEMBL Value Distribution

548
5.0
475
5.5
501
6.0
412
6.5
293
7.0
226
7.5
169
8.0
82
8.5
54
9.0
6
9.5
pChEMBL
Approved Drugs

Approved Drugs

TENOFOVIR ALAFENAMIDE FUMARATE
CHEMBL2364637
Approved 2015
Properties Compare Identifier
TENOFOVIR ALAFENAMIDE
CHEMBL2107825
Approved 2015
Properties Compare Identifier
TELBIVUDINE
CHEMBL374731
Approved 2006
Properties Compare Identifier
ENTECAVIR
CHEMBL5314362
Approved 2005
Properties Compare Identifier
ENTECAVIR ANHYDROUS
CHEMBL713
Approved 2005
Properties Compare Identifier
EMTRICITABINE
CHEMBL885
Approved 2003
Properties Compare Identifier
NITAZOXANIDE
CHEMBL1401
Approved 2002
Properties Compare Identifier
ADEFOVIR DIPIVOXIL
CHEMBL922
Approved 2002
Properties Compare Identifier
TENOFOVIR DISOPROXIL FUMARATE
CHEMBL1486
Approved 2001
Properties Compare Identifier
TENOFOVIR DISOPROXIL
CHEMBL1538
Approved 2001
Properties Compare Identifier
PENCICLOVIR
CHEMBL1540
Approved 1996
Properties Compare Identifier
LAMIVUDINE
CHEMBL141
Approved 1995
Properties Compare Identifier
CYCLOSPORINE
CHEMBL160
Approved 1983
Properties Compare Identifier
ACYCLOVIR
CHEMBL184
Approved 1982
Properties Compare Identifier
Assay Landscape

Assay Landscape

1,536
Total Assays
2,731
Tested Compounds
1
Assay Types
Functional — 1,536 assays, 2,731 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 1,515 2,589 6.0
cell-based format 16 87 7.3
assay format 5 55 7.2

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine